Clinical Trials Browser

Phase 2 × Lymphoma, Non-Hodgkin × tafasitamab × Clear all

NCT05583071 2025-08-13

MTR²

Phase 2 Recruiting

Lymphoma, Non-Hodgkin

NCT01685008 2023-11-07

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Phase 2 Completed

92 enrolled 37 charts

Lymphoma, Non-Hodgkin